ASCO 2017: Effect of Ga-68 PSMA-11 PET on management in patients with recurrent prostate cancer
Chicago, IL (UroToday.com) Up to 30% of prostate cancer (PC) patients after definitive local therapy have biochemical recurrence (BCR). PET imaging of prostate specific membrane antigen (PSMA) has been shown to have a higher sensitivity and specificity compared to conventional imaging. Dr. Tom Hope presented a study attempting to evaluate the impact of PSMA PET on the management of PC patients with BCR following local therapy (Clinical trial information: NCT02611882).
ASCO 2017: Whole blood androgen receptor variant expression and overall survival in metastatic castrate resistant prostate cancer
Chicago, IL (UroToday.com) The detection of full length androgen receptor (AR-FL) or AR variants (AR-Vs) in blood and association with outcomes in metastatic castrate-resistant prostate cancer (mCRPC) is unknown. Dr. Karthik Giridhar presented a study comparing whole blood mRNA expression of AR-FL and AR-Vs to circulating tumor cells (CTCs) for predicting overall survival (OS) and time to treatment failure (TTF).
ASCO 2017: Astellas and Seattle Genetics Announce Updated Enfortumab Vedotin Phase 1 Data in Metastatic Urothelial Cancer
Chicago, IL (UroToday.com) Updated phase 1 data for enfortumab vedotin (ASG-22ME) studied as monotherapy treatment for metastatic urothelial cancer (mUC) was highlighted in an oral presentation at the American Society of Clinical Oncology (ASCO) 52nd Annual Meeting in Chicago.
ASCO 2017: The plasma lipidome in castration-resistant prostate cancer
Chicago, IL (UroToday.com) Biomarker studies of metastatic castration-resistant prostate cancer (mCRPC) have mainly focused on changes in the cancer, however, the host environment and its interactions with cancer is increasingly important, especially given the increasing association of prostate cancer (PC) outcomes and obesity. However, the association of circulating lipids with the clinical outcome of CRPC is unknown and has not been studied. Dr. Lisa Horvath presented an interesting study attempting to find associations between the plasma lipidome and clinical outcome in CRPC.
ASCO 2017: Combination of PDL-1 and PARP inhibition in an unselected population with metastatic castrate-resistant prostate cancer (mCRPC)
Chicago, IL (UroToday.com) Novel therapies in prostate cancer are rapidly developing. PARP inhibitors are a group of inhibitors of the enzyme poly ADP ribose polymerase (PARP), which in turn results in a cell’s inability to repair single-strand DNA breaks. In patients with mutations in DNA repair genes, such as a BRCA1, BRCA2 and PALB2, this second insult can lead to cell death. As >20% of prostate cancers have somatic DNA repair gene defects (DRDs), and clinical trials with PARP inhibitors have demonstrated response rates up to 88% in patients with DRDs,1 PARP inhibitors may have an important role in the management of prostate cancer.
ASCO 2017: Incidence of intrathoracic metastases detected by 68Ga-PSMA-11 PET in early stage prostate cancer
Chicago, IL (UroToday.com) Standard imaging in early stage prostate cancer (PC) has focused on detecting metastases within the abdomen and pelvis. The incidence of intrathoracic (IT) metastasis (lung, mediastinal, or supraclavicular) is unknown, but presumed to be negligible. Whole body 68Ga-PSMA PET has greater sensitivity compared to conventional imaging, enabling a more accurate estimation of IT metastasis.
ASCO 2017: Clinical implications of the 2012 US Preventive Services Task Force PSA screening recommendation in prostate cancer diagnoses and 5-year survival at a Minnesota safety net health care system
Chicago, IL (UroToday.com) Prostate specific antigen (PSA) screening for prostate cancer has declined following the US Preventative Services Task Force (USPSTF) 2012 recommendation. No data exists regarding how screening rates and prostate cancer diagnoses have subsequently changed in a racially diverse patient population. Dr. Kevin Gale presented a study aiming to determine the impact of the USPSTF screening recommendation in the Hennepin Healthcare System (HHS) in the state of Minnesota.